Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for VistaGen Therapeutics, Inc. (VTGN : NSDQ)

• Company Description    VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California. Number of Employees: 21

• Price / Volume Information    Yesterday's Closing Price: $1.19 Daily Weekly Monthly 20 Day Moving Average: 884,391 shares Shares Outstanding: 206.53 (millions) Market Capitalization: $245.77 (millions) Beta: 0.93 52 Week High: $3.55 52 Week Low: $1.06 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -21.19% -13.65% 12 Week -14.39% -7.11% Year To Date -38.97% -27.43%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 343 ALLERTON AVENUE - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-577-3600 fax: 888-482-2602 mflather@vistagen.com http://www.vistagen.com

• General Corporate Information    Officers Shawn K. Singh - Chief Executive Officer; and Director Jon S. Saxe - Chairman H. Ralph Snodgrass - President; Chief Scientific Officer and Director Jerrold D. Dotson - Vice President and Chief Financial Officer Ann M. Cunningham - Director Peer Information VistaGen Therapeutics, Inc. (CORR.) VistaGen Therapeutics, Inc. (RSPI) VistaGen Therapeutics, Inc. (CGXP) VistaGen Therapeutics, Inc. (BGEN) VistaGen Therapeutics, Inc. (GTBP) VistaGen Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 92840H202 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 12/01/21 Next Expected EPS Date: 07/05/22 Share - Related Items Shares Outstanding: 206.53 Most Recent Split Date: (:1) Beta: 0.93 Market Capitalization: $245.77 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.06 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.28 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/05/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.97 Price/Cash Flow: - Price / Sales: 162.55 EPS Growth vs. Year Ago Period: 28.57% vs. Previous Quarter: 28.57% Sales Growth vs. Year Ago Period: 14.01% vs. Previous Quarter: 0.00% ROE 03/31/22 - - 12/31/21 - -44.10 09/30/21 - -36.41 ROA 03/31/22 - - 12/31/21 - -36.99 09/30/21 - -30.38 Current Ratio 03/31/22 - - 12/31/21 - 13.51 09/30/21 - 12.19 Quick Ratio 03/31/22 - - 12/31/21 - 13.51 09/30/21 - 12.19 Operating Margin 03/31/22 - - 12/31/21 - -2,465.94 09/30/21 - -2,183.17 Net Margin 03/31/22 - - 12/31/21 - -2,465.94 09/30/21 - -2,183.17 Pre-Tax Margin 03/31/22 - - 12/31/21 - -2,465.68 09/30/21 - -2,182.90 Book Value 03/31/22 - - 12/31/21 - 0.40 09/30/21 - 0.42 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - - 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©